Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.
Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers.
复制标题
DOI：
10.2147/ott.s50838
复制
发表时间：
2013-11-05
影响因子：
4
通讯作者：
Pichika MR
中科院分区：
文献类型：
--
作者：
Mai CW;Kang YB;Pichika MR
Toll样受体4（TLR-4）是一种具有天然免疫功能的受体。尽管TLR-4活化赋予抗肿瘤反应，但新出现的证据表明TLR-4与肿瘤的发生和进展相关。现在清楚的是，TLR-4的过度活化，通过各种免疫介质，可能会导致免疫反应功能障碍，导致肿瘤发生。不同的癌症在肿瘤发生或肿瘤进展过程中可能具有不同程度的TLR-4参与。在这篇综述中，我们专注于感染和炎症相关的TLR-4在非癌细胞和癌细胞中的激活，以及TLR-4在10种最常见的癌症中的作用的现有证据，即，头颈癌，肺癌，胃肠癌，肝癌，胰腺癌，皮肤癌，乳腺癌，卵巢癌，宫颈癌和前列腺癌。
Toll-like receptor 4 (TLR-4) is well known for its host innate immunity. Despite the fact that TLR-4 activation confers antitumor responses; emerging evidence suggests that TLR-4 is associated with tumor development and progression. It is now clear that overactivation of TLR-4, through various immune mediators, may cause immune response dysfunction, resulting in tumorigenesis. Different cancers could have different extents of TLR-4 involvement during tumorigenesis or tumor progression. In this review, we focus on infection- and inflammation-related TLR-4 activation in noncancer and cancer cells, as well as on the current evidence about the role of TLR-4 in ten of the most common cancers, viz, head and neck cancer, lung cancer, gastrointestinal cancer, liver cancer, pancreatic cancer, skin cancer, breast cancer, ovarian cancer, cervical cancer, and prostate cancer.